These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32299331)

  • 21. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
    Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
    Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
    Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and Safety of a 9-Valent HPV Vaccine.
    Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A
    Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule.
    Tunis MC; Deeks SL;
    Can Commun Dis Rep; 2016 Jul; 42(7):149-151. PubMed ID: 29770021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A
    Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.
    Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A
    Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus epidemiology and vaccine recommendations: selected review of the recent literature.
    Seyferth ER; Bratic JS; Bocchini JA
    Curr Opin Pediatr; 2016 Jun; 28(3):400-6. PubMed ID: 27093357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
    J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
    Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
    Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a
    Gilca V; Sauvageau C; Panicker G; De Serres G; Schiller J; Ouakki M; Unger ER
    Hum Vaccin Immunother; 2019; 15(7-8):1980-1985. PubMed ID: 31017850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls.
    Iwata S; Murata S; Rong Han S; Wakana A; Sawata M; Tanaka Y
    Jpn J Infect Dis; 2017 Jul; 70(4):368-373. PubMed ID: 28003597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of the receipt of the 9-valent human papillomavirus vaccine in the first year after introduction in North Carolina.
    Trogdon JG; Shafer P; Lindsay B; Coyne-Beasley T
    Vaccine; 2018 Feb; 36(10):1310-1315. PubMed ID: 29366705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-11 year-old girls and boys - clinical protocol.
    Zeng Y; Moscicki AB; Sahasrabuddhe VV; Garcia F; Woo H; Hsu CH; Szabo E; Dimond E; Vanzzini S; Mondragon A; Butler V; DeRose H; Chow HS
    BMC Cancer; 2019 Apr; 19(1):290. PubMed ID: 30935375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.